Summary:
Click image to enlargeThe purpose of this study is to measure relative vaccine efficacy (rVE) of mRNA-1010 as compared to an active comparator to prevent the occurrence of the first episode of reverse transcriptase-polymerase chain reaction (RT-PCR) confirmed protocol-defined influenza-like illness (ILI) caused by any influenza A or B virus strains
Criteria:- At least 50 years of age at the time of consent (Screening visit) Male and Female.
- Females of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria: − Has a negative pregnancy test at the Screening visit and on the day of vaccination prior to study vaccine dose being administered on Day 1. − Has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose (Day 1). Adequate female contraception is defined as consistent and correct use of a local health authority-approved contraceptive method in accordance with the product label. − Has agreed to continue adequate contraception through 90 days following study vaccine administration
Qualified Participants May Receive:
Participants will receive up to $820.00